The hydroxycarboxylic acid receptor HCA2 is required for the protective effect of ketogenic diet in epilepsy
Pharmacology Research & Perspectives · 2024
DOI: 10.1002/prp2.70026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2024. Verfasst von Jill C Richardson und 11 weiteren Autor:innen. Beteiligte Einrichtung: Neurosciences Therapeutic Area Unit, GlaxoSmithKline R&D Ltd, Stevenage, UK. Hauptthemen laut MEDLINE: Diet, Ketogenic, Receptors, G-Protein-Coupled, Epilepsy, Mice, Knockout. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: GlaxoSmithKline.
Abstract (Originalsprache)
One third of epilepsy patients are resistant to treatment with current anti‐seizure medications. The ketogenic diet is used to treat some forms of refractory epilepsy, but the mechanism of its action has not yet been elucidated. In this study, we aimed to investigate whether the hydroxycarboxylic acid receptor 2 (HCA2), a known immunomodulatory receptor, plays a role in mediating the protective effect of this diet. We demonstrate for the first time that selective agonists at this receptor can directly reduce seizures in animal models. Agonists also reduce network activity in rodent and human brain slices. Ketogenic diet is known to increase circulating levels of endogenous HCA2 agonists, and we show that the effect of ketogenic diet in reducing seizures in the 6 Hz seizure model is negated in HCA2‐deficient mice. Our data support the potential of HCA2 as a target for the treatment of epilepsy and potentially for neurodegenerative diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neurosciences Therapeutic Area Unit, GlaxoSmithKline R&D Ltd, Stevenage, UK.
- InterVivo Solutions, Toronto, Canada.
- Transpharmation Ltd., South Mimms, UK.
- Institute of Neuroscience, University of Newcastle, Newcastle, UK.
- Discipline of Physiology, School of Medicine, Trinity College Dublin, Dublin 2, Ireland.
- In vitro and in vivo Translation, GlaxoSmithKline R&D Ltd, Stevenage, UK.
ORCID-Profile: Jill C Richardson, Mark Cunningham, Andrew J Brown
Förderung
- GlaxoSmithKline
Zitieren
APA
Richardson, J. C., Higgins, G. A., Upton, N., Massey, P., Cunningham, M., Wilson, S., Holenz, J., Taylor, C., Lavrov, A., Lin, H., Matsuoka, Y., & Brown, A. J. (2024). The hydroxycarboxylic acid receptor HCA2 is required for the protective effect of ketogenic diet in epilepsy. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70026
Vancouver
Richardson JC, Higgins GA, Upton N, Massey P, Cunningham M, Wilson S, et al. The hydroxycarboxylic acid receptor HCA2 is required for the protective effect of ketogenic diet in epilepsy. Pharmacology Research & Perspectives. 2024. doi:10.1002/prp2.70026
BibTeX
@article{Richardson2024,
author = {Richardson, Jill C and Higgins, Guy A and Upton, Neil and Massey, Peter and Cunningham, Mark and Wilson, Steve and Holenz, Joerg and Taylor, Colleen and Lavrov, Arseniy and Lin, Hong and Matsuoka, Yasuji and Brown, Andrew J},
title = {The hydroxycarboxylic acid receptor HCA2 is required for the protective effect of ketogenic diet in epilepsy},
journal = {Pharmacology Research & Perspectives},
year = {2024},
doi = {10.1002/prp2.70026}
}
EUVIMED